What does PHARMA LINK do?

PHARMA LINK is a pharmacy in Lichtervelde. Public Limited, started on 12 May 1998, 1 establishment.

What is the address of PHARMA LINK?

The registered office of PHARMA LINK is located at Neerstraat 3, 8810 Lichtervelde.

Is PHARMA LINK still active?

Yes. According to the CBE (30 October 2026) PHARMA LINK is active, legal situation “Normale toestand”, started on 12 May 1998.

Is PHARMA LINK registered on Peppol?

Yes, PHARMA LINK is registered on the Peppol network with ID 0208:0463340789.

What is the enterprise number of PHARMA LINK?

The enterprise number of PHARMA LINK is BE0463340789.

When was PHARMA LINK founded?

PHARMA LINK was founded on 12 May 1998.

Who are the directors of PHARMA LINK?

According to the 2025 annual accounts, the directors of PHARMA LINK are: Charlotte Delobel.

Is PHARMA LINK a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 May 1998; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMA LINK make in 2025?

PHARMA LINK posted a profit after taxes of € 128,563 in financial year 2025.

What is the revenue of PHARMA LINK?

As a small company, PHARMA LINK is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 335,992.

How much does an employee at PHARMA LINK earn?

The average wage cost per full-time employee at PHARMA LINK was € 59,200 in 2025: staff costs of € 88,864 for 1.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA LINK have?

According to the 2025 annual accounts, PHARMA LINK has 1.5 full-time equivalents (FTE).

Does PHARMA LINK have a website?

Yes, PHARMA LINK has a website at apotheekdelobel.be.

PHARMA LINK (Public Limited) - Lichtervelde

Dossier PHARMA LINK, printed on 30 October 2026 from databakkes.be/en/0463340789/pharma-link. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMA LINK from Lichtervelde, company number BE0463340789, closed financial year 2025 with a result of € 128,563 after tax. For that financial year PHARMA LINK recorded a gross margin of € 335,992 and equity of € 149,586. Compared with financial year 2024, the result moved from € 230,219 to € 128,563. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.

What it is worth Healthy

€ 149,586

▼ 48% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 128,563

▼ 44% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 103,671

▲ 11% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 268,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

1.5

▼ 0.7 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 88,864

▲ 20% vs 2024

€ 59,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 19,411

▲ € 18,352 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 242,525

▼ 12% vs 2024

€ 33,878 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 253,375

▲ 84% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 7,672

▼ 24% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 340,100 Gross margin 2022: € 340,100 First fiscal year in the series	€ 380,269 Gross margin 2023: € 380,269 ▲ 12% vs 2022 (€ 340,100) Favourable step	€ 456,634 Gross margin 2024: € 456,634 ▲ 20% vs 2023 (€ 380,269) Favourable step	€ 335,992 Gross margin 2025: € 335,992 ▼ 26% vs 2024 (€ 456,634) Unfavourable step	▼ 26%
Profit after taxes	€ 155,735 Profit after taxes 2022: € 155,735 First fiscal year in the series	€ 179,447 Profit after taxes 2023: € 179,447 ▲ 15% vs 2022 (€ 155,735) Favourable step	€ 230,219 Profit after taxes 2024: € 230,219 ▲ 28% vs 2023 (€ 179,447) Favourable step	€ 128,563 Profit after taxes 2025: € 128,563 ▼ 44% vs 2024 (€ 230,219) Unfavourable step	▼ 44%
Equity	€ 347,707 Equity 2022: € 347,707 First fiscal year in the series	€ 296,804 Equity 2023: € 296,804 ▼ 15% vs 2022 (€ 347,707) Unfavourable step	€ 289,022 Equity 2024: € 289,022 ▼ 3% vs 2023 (€ 296,804) Unfavourable step	€ 149,586 Equity 2025: € 149,586 ▼ 48% vs 2024 (€ 289,022) Unfavourable step	▼ 48%
Total debts	€ 516,946 Total debts 2022: € 516,946 First fiscal year in the series	€ 752,803 Total debts 2023: € 752,803 ▲ 46% vs 2022 (€ 516,946) Unfavourable step	€ 665,522 Total debts 2024: € 665,522 ▼ 12% vs 2023 (€ 752,803) Favourable step	€ 874,338 Total debts 2025: € 874,338 ▲ 31% vs 2024 (€ 665,522) Unfavourable step	▲ 31%
Cash	€ 101,007 Cash 2022: € 101,007 First fiscal year in the series	€ 138,554 Cash 2023: € 138,554 ▲ 37% vs 2022 (€ 101,007) Favourable step	€ 93,379 Cash 2024: € 93,379 ▼ 33% vs 2023 (€ 138,554) Unfavourable step	€ 103,671 Cash 2025: € 103,671 ▲ 11% vs 2024 (€ 93,379) Favourable step	▲ 11%
Land & buildings	€ 331,746 Land & buildings 2022: € 331,746 First fiscal year in the series	€ 312,457 Land & buildings 2023: € 312,457 ▼ 6% vs 2022 (€ 331,746) Unchanged	€ 278,506 Land & buildings 2024: € 278,506 ▼ 11% vs 2023 (€ 312,457) Unchanged	€ 244,555 Land & buildings 2025: € 244,555 ▼ 12% vs 2024 (€ 278,506) Unchanged	▼ 12%
Retained profit	€ 285,707 Retained profit 2022: € 285,707 First fiscal year in the series	€ 234,804 Retained profit 2023: € 234,804 ▼ 18% vs 2022 (€ 285,707) Unfavourable step	€ 227,022 Retained profit 2024: € 227,022 ▼ 3% vs 2023 (€ 234,804) Unfavourable step	€ 87,586 Retained profit 2025: € 87,586 ▼ 61% vs 2024 (€ 227,022) Unfavourable step	▼ 61%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 230,350 Dividend 2023: € 230,350 Unchanged (€ 0) Unchanged	€ 238,000 Dividend 2024: € 238,000 ▲ 3% vs 2023 (€ 230,350) Unchanged	€ 268,000 Dividend 2025: € 268,000 ▲ 13% vs 2024 (€ 238,000) Unchanged	▲ 13%
Bank debt	€ 366,174 Bank debt 2022: € 366,174 First fiscal year in the series	€ 321,320 Bank debt 2023: € 321,320 ▼ 12% vs 2022 (€ 366,174) Favourable step	€ 275,872 Bank debt 2024: € 275,872 ▼ 14% vs 2023 (€ 321,320) Favourable step	€ 242,525 Bank debt 2025: € 242,525 ▼ 12% vs 2024 (€ 275,872) Favourable step	▼ 12%
Balance sheet total	€ 864,653 Balance sheet total 2022: € 864,653 First fiscal year in the series	€ 1,049,607 Balance sheet total 2023: € 1,049,607 ▲ 21% vs 2022 (€ 864,653) Unchanged	€ 954,545 Balance sheet total 2024: € 954,545 ▼ 9% vs 2023 (€ 1,049,607) Unchanged	€ 1,023,924 Balance sheet total 2025: € 1,023,924 ▲ 7% vs 2024 (€ 954,545) Unchanged	▲ 7%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	1 Employees (FTE) 2023: 1 Unchanged (1) Unchanged	2.2 Employees (FTE) 2024: 2.2 ▲ 1.2 vs 2023 (1) Unchanged	1.5 Employees (FTE) 2025: 1.5 ▼ 0.7 vs 2024 (2.2) Unchanged	▼ 0.7

Key figures of PHARMA LINK, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA LINK?

What happened at PHARMA LINK in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Charlotte Delobel stepped down as director. NBB
Jun 23, 2026 New annual accounts for financial year 2025: profit of € 128,563 (▼ 44% vs 2024). Source: NBB ↗
2023 Charlotte Delobel became a director. NBB
Jul 15, 1998 New establishment in Lichtervelde. KBO
May 12, 1998 Start of the company according to the CBE. KBO

In short

From € 155,735 profit in 2022 to € 128,563 profit in 2025.

Paid € 241,567 in corporate taxes since 2022.

Best year ever: 2024, with € 230,219 profit.

On average € 224,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Lobelia Pharma 99.2%

The stake of Lobelia Pharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMA LINK

The shares are held by Lobelia Pharma (99.2%).

Directors

According to the 2025 annual accounts

Charlotte Delobel

Director

Also active at: Lobelia Pharma, LOBELIA INVESTMENT AND MANAGEMENT

since 2023 · until 2029

Shareholders

Lobelia Pharma

99.2%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Neerstraat 3

8810 Lichtervelde

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS apotheekdelobel.be

Canonical: https://www.apotheekdelobel.be/

Technologies

ApacheElementorFont AwesomeGoogle MapsPHPSwiperUIKitVarnishWooCommerceWordPressYoast SEOjQueryjQuery UIlazysizes

Hosting & Email

Email provider

one.com Mail

Hosting

ONECOM, DK

Website info

HTTPS Ja

Indexable pages 1

Languages EN

Features

Webshop

Security

✓ HTTPS

✗ SPF

✓ DMARC

Network

✓ IPv6

Details

Company number

0463.340.789

VAT number

BE 0463.340.789

Registered office

Neerstraat 3, 8810 Lichtervelde

Names & denominations

PHARMA LINK

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

12 May 1998

Peppol

Active · Active since 21 Nov 2025

Contact

apotheekdelobel.be

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA LINK

Financials

What happened to PHARMA LINK?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions